Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Sumanta Kumar Pal, Laurence Albigès, Nizar M. Tannir et al.|Journal of Clinical Oncology|2024Cited by 9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010José A. Karam, Viraj A. Master, Robert G. Uzzo et al.|European Urology Oncology|2024Cited by 4
Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).Hedyeh Ebrahimi, Alex Chehrazi‐Raffle, Joann Hsu et al.|Journal of Clinical Oncology|2025Cited by 1
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.Sumanta Kumar Pal, Cristina Suárez, Thomas Powles et al.|Journal of Clinical Oncology|2024Cited by 1
Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.Antonio Cigliola, Andrea Necchi, Brigida Anna Maiorano et al.|Journal of Clinical Oncology|2026Cited by 1